Efficacy of a guideline-recommended risk-reduction program to improve cardiovascular and limb outcomes in patients with peripheral arterial disease

JAMA Surgery

Volumn 151, Issue 8, 2016, Pages 742-750

  Hussain, Mohamad A ^a,b   Al Omran, Mohammed ^a,b,c,d   Mamdani, Muhammad ^c,d,e,f,g,h   Eisenberg, Naomi ⁱ   Premji, Azra ^b   Saldanha, Lisa ^b   Wang, Xuesong ^h   Verma, Subodh ^a,b,c,d   Lindsay, Thomas F ^b,i  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g Applied Health Research Centre   (Canada)

^h INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; GLUCOSE BLOOD LEVEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTERIAL STENT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; BRAIN ISCHEMIA; BYPASS SURGERY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GLYCEMIC CONTROL; HEART FAILURE; HOSPITALIZATION; HUMAN; LEG AMPUTATION; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ONTARIO; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK MANAGEMENT; RISK REDUCTION; SMOKING CESSATION; VASCULAR SURGEON; AMPUTATION; ANGIOPLASTY; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; COMPLICATION; GLUCOSE BLOOD LEVEL; LIMB; METABOLISM; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PROTOCOL COMPLIANCE; STATISTICS AND NUMERICAL DATA; STENT; STROKE; SURGERY; TIME FACTOR;

AGED; AMPUTATION; ANGIOPLASTY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; EXTREMITIES; FEMALE; GUIDELINE ADHERENCE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ONTARIO; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RISK REDUCTION BEHAVIOR; SMOKING CESSATION; STENTS; STROKE; TIME FACTORS;

EID: 84998610639     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2016.0415     Document Type: Article

References (37)

1. Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012;308(16):1660-1667.
2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738-743.
3. Fowkes FG, Murray GD, Butcher I, et al; Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: Ameta-Analysis. JAMA. 2008;300(2):197-208.
4. Fowkes FGR, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 2013;382(9901):1329-1340.
5. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(13):1425-1443.
6. Makowsky MJ, McAlister FA, Galbraith PD, et al; Alberta Provincial Program for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Lower extremity peripheral arterial disease in individuals with coronary artery disease: prognostic importance, care gaps, and impact of therapy. Am Heart J. 2008;155(2):348-355.
7. Bhatt DL, Steg PG, Ohman EM, et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-189.
8. Subherwal S, Patel MR, Kober L, et al.Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012;126(11): 1345-1354.
9. Hasimu B, Li J, Yu J, et al. Evaluation of medical treatment for peripheral arterial disease in Chinese high-risk patients. Circ J. 2007;71(1):95-99.
10. Flu HC, Tamsma JT, Lindeman JHN, Hamming JF, Lardenoye JHP. A systematic review of implementation of established recommended secondary prevention measures in patients with PAOD. Eur J Vasc Endovasc Surg. 2010;39(1):70-86.
11. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
12. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
14. Al-Omran M, Verma S, Lindsay TF. Suboptimal use of risk reduction therapy in peripheral arterial disease patients at a major teaching hospital. Ann Saudi Med. 2011;31(4):371-375.
15. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.
16. Al-Omran M, Mamdani MM, Lindsay TF, Melo M, Juurlink DN, Verma S; Systematic Assessment of Vascular Risk Investigators. Suboptimal use of statin therapy in elderly patients with atherosclerosis: A population-based study. J Vasc Surg. 2008;48(3):607-612.
17. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354(13):1352-1361.
18. Al-Omran M, Tu JV, Johnston KW, Mamdani MM, Kucey DS. Outcome of revascularization procedures for peripheral arterial occlusive disease in Ontario between 1991 and 1998: A population-based study. J Vasc Surg. 2003;38(2): 279-288.
19. Fan J, Arruda-Olson AM, Leibson CL, et al. Billing code algorithms to identify cases of peripheral artery disease from administrative data. J AmMed Inform Assoc. 2013;20(e2):e349-e354.
20. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.
21. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study. Stat Med. 2007;26(4):734-753.
22. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
23. Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J AmHeart Assoc. 2014;3(2):e000697.
24. Ardati AK, Kaufman SR, Aronow HD, et al. The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions. Circ Cardiovasc Interv. 2012; 5(6):850-855.
25. Feringa HH, vanWaning VH, Bax JJ, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J AmColl Cardiol. 2006;47(6): 1182-1187.
26. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev. 2011;(1):CD001561.
27. Lager KE, Mistri AK, Khunti K, Haunton VJ, Sett AK, Wilson AD. Interventions for improving modifiable risk factor control in the secondary prevention of stroke. Cochrane Database Syst Rev. 2014;5:CD009103.
28. Hirsch AT, Murphy TP, Lovell MB, et al; Peripheral Arterial Disease Coalition. Gaps in public knowledge of peripheral arterial disease: The first national PAD public awareness survey. Circulation. 2007;116(18):2086-2094.
29. Lovell M, Harris K, Forbes T, et al; Peripheral Arterial Disease Coalition. Peripheral arterial disease: lack of awareness in Canada. Can J Cardiol. 2009;25(1):39-45.
30. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11): 1317-1324.
31. Chan AW, Henderson MA. Reorganization of vascular care in Canada. Can J Cardiol. 2010;26(1): 43-44.
32. Holbrook A, Pullenayegum E, Thabane L, et al. Shared electronic vascular risk decision support in primary care: Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III) randomized trial. Arch Intern Med. 2011;171(19):1736-1744.
33. Vernooij JW, Kaasjager HA, van der Graaf Y, et al; SMARTStudy Group. Internet based vascular risk factor management for patients with clinically manifest vascular disease: randomised controlled trial. BMJ. 2012;344:e3750.
34. Evans CD, Eurich DT, Taylor JG, Blackburn DF. The Collaborative Cardiovascular Risk Reduction in Primary Care (CCARP) Study. Pharmacotherapy. 2010;30(8):766-775.
35. Brouwer BG, Visseren FLJ, Algra A, et al. Effectiveness of a hospital-based vascular screening programme (SMART) for risk factor management in patients with established vascular disease or type 2 diabetes: A parallel-group comparative study. J Intern Med. 2010;268(1):83-93.
36. Juurlink DN, Preyra C, Coxford R, et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. Toronto, ON, Canada: Institute for Clinical Evaluative Sciences; 2006.
37. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, Revisions 9 and 10. Stroke. 2005;36 (8):1776-1781.